Another metaanalysis done by Katsanos et al. (1) from eight randomized trials show that amputation free survival was worse with Paclitaxel coated balloon (PCB) in infrapopliteal arteries for the treatment of critical limb ischemia. Authors also, show that the harm signal was evident when examining the high dose (3.0-3.5 micrograms/mm2) device and attenuated below significance in case of a low-dose (2 micrograms/mm2) device.